Mr. Ault founded Alzamend Neuro, Inc., a biotechnology firm dedicated to finding the treatment, prevention and cure for Alzheimer’s Disease on February 25, 2016 and has served as its Chairman ever since.
Mr. Ault is a seasoned business professional and entrepreneur who has spent more than twenty-seven years identifying value in various financial markets including equities, fixed income, commodities, and real estate. On March 16, 2017, Mr. Ault was appointed Executive Chairman of the Board for DPW Holdings, Inc. (“DPW”), formerly known as Digital Power Corporation and on December 28, 2017, Mr. Ault was appointed Chief Executive Officer for DPW. Mr. Ault has served as Chairman of Ault & Company, a holding company since December 2015, and as Chairman of Avalanche International Corp since September 2014, a publicly traded company. Since January 2011, Mr. Ault has been the Vice President of Business Development for MCKEA Holdings, LLC, a family office. Through this latter position, Mr. Ault has consulted for a few publicly traded and privately held companies, providing each of them the benefit of his diversified experience, that range from development stage to seasoned businesses.
Mr. Ault became majority shareholder of Franklin Capital Corp and was elected to its board of directors in July 2004 and became its Chairman and Chief Executive Officer in October 2004 serving until January 2006, and again from July 2006 to January 2007. In April 2005, the company changed its name to Patient Safety Technologies, Inc. (OTCBB: PSTX, OTCQB: PSTX) (“PST”) and purchased SurgiCount Medical, Inc. Stryker Corporation (NYSE: SYK) acquired PST at the beginning of 2014 in a deal valued at approximately one hundred twenty million dollars ($120,000,000). PST’s wholly owned operating subsidiary, SurgiCount Medical, Inc., is the company that developed the SafetySponge® System; a bar coding technology for inventory control that aims to detect and prevent the incidence of foreign objects left in the body after surgery.
What is Milton C. Ault, III.'s net worth?
The estimated net worth of Milton C. Ault, III. is at least $1.23 million as of October 7th, 2024. Mr. Ault, III. owns 945,000 shares of Alzamend Neuro stock worth more than $1,228,500 as of November 22nd. This net worth approximation does not reflect any other investments that Mr. Ault, III. may own. Learn More about Milton C. Ault, III.'s net worth.
How do I contact Milton C. Ault, III.?
Has Milton C. Ault, III. been buying or selling shares of Alzamend Neuro?
Milton C. Ault, III. has not been actively trading shares of Alzamend Neuro during the past quarter. Most recently, on Tuesday, August 6th, Milton C. Ault III bought 75 shares of Alzamend Neuro stock. The stock was acquired at an average cost of $2.75 per share, with a total value of $206.25. Following the completion of the transaction, the director now directly owns 77,268 shares of the company's stock, valued at $212,487. Learn More on Milton C. Ault, III.'s trading history.
Who are Alzamend Neuro's active insiders?
Are insiders buying or selling shares of Alzamend Neuro?
During the last year, Alzamend Neuro insiders bought shares 7 times. They purchased a total of 803 shares worth more than $7,024.05. The most recent insider tranaction occured on August, 6th when Director Milton C Ault III bought 75 shares worth more than $206.25. Insiders at Alzamend Neuro own 10.6% of the company.
Learn More about insider trades at Alzamend Neuro. Information on this page was last updated on 8/6/2024.
